



International Federation of Gynecology and Obstetrics



COMMITTEE FOR UROGYNAECOLOGY AND PELVIC FLOOR

MEMBER:

TSUNG-HSIEN (CHARLES) SU, CHAIR (TAIWAN)

DAVID RICHMOND, CO-CHAIR (UK)

CHITTARANJAN PURANDARE, EX OFFICIO (INDIA)

OSCAR CONTERAS ORTIS (ARGENTINA)

BOBFREEMAN (IUGA, UK)

PETER DE JONG (SOUTH AFRICA)

PAUL RISS (AUSTRIA)

STEVEN SWIFT (USA)



FIGO

INTERNATIONAL FEDERATION
OF
GYNECOLOGY & OBSTETRICS

OVERACTIVE BLADDER: DIAGNOSIS AND MANAGEMENT

Overactive bladder (OAB)

- OAB is a symptom syndrome.
- ICS (International Continence Society, 2002) definition:
 - Urgency, with or without urge incontinence, usually with frequency and nocturia.
 - In the absence of obvious pathologic or metabolic disorders (such as UTI, BPE or bladder cancer, which might cause such symptoms).



FIGO

INTERNATIONAL FEDERATION
OF
GYNECOLOGY & OBSTETRICS

Prevalence of OAB

- European: 16.6% (age ≥ 40 y/o)
 - female: 17.4%
 - male: 15.6%
- USA: 16.4% (age > 18 y/o)
 - female: 16.9%
 - male: 16.0%
- Taiwan: 16.9% (age > 30 y/o)
 - female: 18.3%
 - male: 16.0%

Milsom et al. *BJU Int* 2001
Stewart et al. *World J Urol.* 2003
Yu et al. *Urol Int* 2006

OAB Symptoms

Frequency

- Daytime frequency: complaint by the patient who considers that they void too often by day
- Nocturia (urination at night): complaint that the patient has to wake up at night 1 or more times to void

Urgency (core symptom)

- Sudden, compelling desire to pass urine that is difficult to defer

Urge Incontinence

Involuntary leakage preceded by urgency




OAB



FIGO

INTERNATIONAL FEDERATION
OF
GYNECOLOGY & OBSTETRICS

Impact on Quality of Life





OABSS

TABLE I. Overactive bladder symptom score*

Question	Frequency	Score
How many times do you typically urinate from waking in the morning until sleeping at night?	≤7	0
	8–14	1
	≥15	2
How many times do you typically wake up to urinate from sleeping at night until waking in the morning?	0	0
	1	1
	2	2
	≥3	3
How often do you have a sudden desire to urinate, which is difficult to defer?	Not at all	0
	Less than once a week	1
	Once a week or more	2
	About once a day	3
	2–4 times a day	4
	5 times a day or more	5
How often do you leak urine because you cannot defer the sudden desire to urinate?	Not at all	0
	Less than once a week	1
	Once a week or more	2
	About once a day	3
	2–4 times a day	4
	5 times a day or more	5

* Patients were instructed to circle the score that best applied to their urinary condition during the past week; the overall score was the sum of the four scores.



FIGO

INTERNATIONAL FEDERATION
OF
GYNECOLOGY & OBSTETRICS

OAB-q

	Yes	No
Do you urinate more than 8 times in a 24-hour period?		
Do you frequently get up 2 or more times during the night to go to the bathroom?		
Do you have the uncontrollable urges to urinate that sometime resulted in wetting accidents?		
Do you frequently limit your fluid intake when you are away from home so that you won't have to worry about finding a bathroom?		
When you are in a new place, do you make sure you know where the bathroom is?		
Do you avoid places if you think there won't a bathroom nearby?		
Do you frequently have strong , sudden urges to urinate?		
Do you go to he bathroom so often that it interferes with the things you want to do?		
Do you use pads to protect your clothes from wetting?		



Goal for treatment of OAB

- To improve symptoms that cause a problem for the individual patient.
- **Urgency** is the key symptom to OAB treatment.


Management of OAB

- **Standard first-line therapy**
 - Behavior therapy
 - Pharmacological therapy
- **Specialized therapy**
 - Neuromodulation
 - Reconstructive and invasive surgery
 - Botulinum neurotoxin-A injections

Behavior therapy

- **Initial treatment (first line) (level 1 evidence)**
 - **Lifestyle intervention (behavior modification)**
 - Weight reduction, caffeine reduction, smoking cessation, modified fluid intake (fluid reduction, avoid water-containing foods, avoid fluid intake from 4 hours before sleep, empty bladder before sleep or going out)
 - **Pelvic floor muscle training**
 - **Bladder retraining**

Pharmacotherapy for OAB





Pharmacological therapy

Anticholinergic agents

- Antimuscarinics are efficacious, safe, and well-tolerated treatments for OAB.
- These agents currently remain the **first-line** pharmacologic treatment for OAB.

Antimuscarinic mechanism of action

– **Detrusor muscle**

→ inhibit Ach binding to M receptor

→ stabilize det muscle

→ ↑ bladder capacity

– **Sensory receptors** in uro/suburothelium

→ ↓ afferent nerve activity (A δ -fiber and C-fiber)

– Significant reductions in urinary frequency, urgency and UUI episodes

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

Christopher R. Chapple^{a,*}, Vik Khullar^b, Zahava Gabriel^c, Dominic Muston^c,
Caty Ebel Bitoun^d, David Weinstein^d

- All antimuscarinics reviewed were more effective than placebo
- Mean changes in
 - Number of incontinence episodes
 - Number of micturitions per day
 - Volume voided per micturitions
 - Number of urgency episodes per day (fesoterodine, propiverine, solifenacin, tolterodine)*

* The data for the remaining drugs in the study was not available for these parameters



FIGO

INTERNATIONAL FEDERATION
OF
GYNECOLOGY & OBSTETRICS

Antimuscarinic agents

	Level	Grade	
Antimuscarinics			
Tolterodine	1	A	(highly recommended)
Trosipium	1	A	(highly recommended)
Darifenacin	1	A	(highly recommended)
Solifenacin	1	A	(highly recommended)
Propantheline	2	B	(Recommended)
Atropine, hyoscyamine	3	C	(optional)
Mixed Action Drugs			
Oxybutynin (muscle relaxant effect)	1	A	(highly recommended)
Propiverine (CC blocker)	1	A	(highly recommended)
Dicyclomine	3	C	(Optional)
Flavoxate	2	D	(possible)





FIGO

INTERNATIONAL FEDERATION
OF
GYNECOLOGY & OBSTETRICS

Adverse events of antimuscarinics

- Due to inhibition of muscarinic receptors in organs other than bladder
- Dry mouth: most common
- Constipation: 2nd most common
- Blurred vision
- Cardiac effect: \uparrow HR, QT prolongation
- CNS effect: Dizziness, insomnia, cognitive impairment

Pharmacotherapy for OAB



Novel β 3 agonist

- Japan approval in 2011: 25 mg/day dose level
- FDA approval in 2012 June: 25 or 50 mg/day dose in the USA
- Europe and Canada
- For symptomatic treatment of urgency, increased micturition frequency and/or UUI~ OAB syndrome.

Anticholinergic drugs vs. $\beta 3$ agonist

- **Anticholinergic drugs:**

 - ~first-line pharmacologic treatment for OAB

- **$\beta 3$ agonist :**

 - ~As second-line treatment for OAB p'ts who are poor responders or intolerant to anticholinergics.

 - ~ May be considered as first-line treatment in the future

Toxins

	Level of evidence	Grade of recommendation
Botulinum toxin (neurogenic)	2	A
Botulinum toxin (idiopathic)	3	B
Capsaicin (neurogenic)	2	C
Resiniferatoxin (idiopathic)	2	C